Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 23 Feb 2021 |
| Genmab announces initiation of share buy-back program | 23 Feb 2021 |
| Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines | 22 Feb 2021 |
| Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer | 10 Feb 2021 |
| Genmab A/S has published its Articles of Association | 5 Feb 2021 |
| CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis | 29 Jan 2021 |